PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|February 15, 2017
Synergy Rx Pharmacy Issues Recall Due to Lack of Sterility
Author(s)Pharmaceutical Technology Editors
The company has voluntarily recalled all lots of of human chorionic gonadotropin because of a lack of sterility assurance.
Advertisement
On Feb. 14, 2017, Synergy Rx Pharmacy announced a voluntary recall of all lots of of human chorionic gonadotropin (HCG) 5000 units/vial and 11,000 units/vial, distributed between June 1, 2016 and Dec. 22, 2016, because of a lack of sterility assurance. The recalled lots, which were packaged in 15 mL serum glass vials, were distributed to physician offices and clinics in Arizona, California, Wisconsin, and Minnesota.
As of Feb. 14, the company had not received any reports of adverse events due to the recalled product but it warns that use a product intended to be sterile that is not sterile could result in serious infections. The company is advising customers to stop use of the product and return any unused lots. Adverse events can be reported to FDA at
Source:
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
In commercial tablet or capsule operations, validation helps protect the site’s ability to produce, release, and supply product without repeated disruption. This article discusses validation as a technical control system that supports manufacturing continuity.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
3
FDA's IND Pilot Puts CMC Review First
4
Successful Internal Audit Planning and Execution
5